JP2021515806A5 - - Google Patents

Info

Publication number
JP2021515806A5
JP2021515806A5 JP2020568847A JP2020568847A JP2021515806A5 JP 2021515806 A5 JP2021515806 A5 JP 2021515806A5 JP 2020568847 A JP2020568847 A JP 2020568847A JP 2020568847 A JP2020568847 A JP 2020568847A JP 2021515806 A5 JP2021515806 A5 JP 2021515806A5
Authority
JP
Japan
Prior art keywords
binding
antigen
binding protein
protein according
triple
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020568847A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021515806A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/055207 external-priority patent/WO2019166650A1/en
Publication of JP2021515806A publication Critical patent/JP2021515806A/ja
Publication of JP2021515806A5 publication Critical patent/JP2021515806A5/ja
Pending legal-status Critical Current

Links

JP2020568847A 2018-03-02 2019-03-01 三重特異性抗原結合タンパク質 Pending JP2021515806A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862637470P 2018-03-02 2018-03-02
US62/637,470 2018-03-02
PCT/EP2019/055207 WO2019166650A1 (en) 2018-03-02 2019-03-01 Trispecific antigen binding proteins

Publications (2)

Publication Number Publication Date
JP2021515806A JP2021515806A (ja) 2021-06-24
JP2021515806A5 true JP2021515806A5 (cg-RX-API-DMAC7.html) 2022-03-09

Family

ID=65802034

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020568847A Pending JP2021515806A (ja) 2018-03-02 2019-03-01 三重特異性抗原結合タンパク質

Country Status (9)

Country Link
US (2) US20200062858A1 (cg-RX-API-DMAC7.html)
EP (1) EP3759146A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021515806A (cg-RX-API-DMAC7.html)
KR (1) KR20210028140A (cg-RX-API-DMAC7.html)
CN (1) CN112119099A (cg-RX-API-DMAC7.html)
AU (1) AU2019228128A1 (cg-RX-API-DMAC7.html)
CA (1) CA3089230A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020009116A (cg-RX-API-DMAC7.html)
WO (1) WO2019166650A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
CN106397592A (zh) * 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
CA3078969A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN119306844A (zh) 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法
EP3816185A1 (en) * 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
JP7461078B2 (ja) 2019-11-08 2024-04-03 ナノテンパー・テクノロジーズ・ゲーエムベーハー 溶液中の粒子の特徴付け
JP7369297B2 (ja) 2019-12-17 2023-10-25 ファイザー・インク Cd47、pd-l1に特異的な抗体、およびその使用
US20230406955A1 (en) * 2020-10-22 2023-12-21 Janux Therapeutics, Inc. Antibodies targeting her2 and cd3 and uses thereof
CN114853897B (zh) * 2021-04-15 2024-01-26 北京大学深圳研究生院 抗cd19/cd22/cd3三特异性抗体及用途
CA3220878A1 (en) * 2021-06-03 2022-12-08 Harpoon Therapeutics, Inc. Bcma targeting trispecific proteins and methods of use
CN118201961A (zh) * 2021-09-16 2024-06-14 Gt生物制药公司 Pd-l1靶向融合蛋白及其使用方法
CN114371282B (zh) * 2021-12-30 2025-07-11 上海药明生物技术有限公司 一种评估抗原沉默效应对抗体药效影响的方法及其应用
EP4754149A1 (en) * 2023-07-29 2026-06-10 Shanghai Kaijin Biotechnology , Ltd Modified type e multi-specific antibodies
WO2025109119A1 (en) 2023-11-22 2025-05-30 Priothera Sas Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
EP1049787B1 (en) * 1998-01-23 2004-11-24 Vlaams Interuniversitair Instituut voor Biotechnologie Multipurpose antibody derivatives
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP2014680A1 (en) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
JP6400470B2 (ja) * 2011-05-16 2018-10-03 ジェネロン(シャンハイ)コーポレイション リミテッド 多重特異性Fab融合タンパク質および使用法
KR101870555B1 (ko) 2011-08-23 2018-06-22 로슈 글리카트 아게 T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Bcmaに対する抗体の選択のための方法
SG11201702401RA (en) * 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
HK1245171A1 (zh) 2014-11-26 2018-08-24 Xencor, Inc. 结合cd3和cd38的异二聚体抗体
US10383929B2 (en) 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
WO2016115274A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
EP3165536A1 (en) * 2015-11-09 2017-05-10 Ludwig-Maximilians-Universität München Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition
EP3390454B1 (en) 2015-12-17 2026-02-04 University of Maryland, Baltimore County A recombinant bi-specific polypeptide for coordinately activating tumor-reactive t-cells and neutralizing immune suppression
US20190031785A1 (en) * 2016-01-13 2019-01-31 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
UA126657C2 (uk) 2016-02-03 2023-01-11 Емджен Рісерч (Мюнік) Ґмбг ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font>
EP4086285A1 (en) 2016-02-25 2022-11-09 Cell Medica Switzerland AG Binding members to pd-l1
US11291721B2 (en) * 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
EP3443006B1 (en) * 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
EP3458481A4 (en) 2016-05-18 2020-07-29 Mayo Foundation for Medical Education and Research TARGETING PD-L1 ON TUMOR CELLS
HRP20251020T1 (hr) 2016-05-20 2025-10-24 Harpoon Therapeutics, Inc. Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3
EP3252078A1 (en) * 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
PL3896091T3 (pl) 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
WO2018071777A1 (en) 2016-10-14 2018-04-19 Harpoon Therapeutics, Inc. Innate immune cell trispecific binding proteins and methods of use
US11124577B2 (en) * 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
WO2019005637A2 (en) * 2017-06-25 2019-01-03 Systimmune, Inc. MULTIPECIFIC ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF

Similar Documents

Publication Publication Date Title
JP2020506971A5 (cg-RX-API-DMAC7.html)
JP2020521448A5 (cg-RX-API-DMAC7.html)
JP2024099850A5 (cg-RX-API-DMAC7.html)
JP2019532619A5 (cg-RX-API-DMAC7.html)
JP2020522473A5 (cg-RX-API-DMAC7.html)
JP2021534096A5 (cg-RX-API-DMAC7.html)
JP2020531438A5 (ja) Nkg2d、cd16、およびhla−eに結合するタンパク質
JP2013545455A5 (cg-RX-API-DMAC7.html)
JP2020063262A5 (cg-RX-API-DMAC7.html)
JP2022533538A5 (cg-RX-API-DMAC7.html)
JP2021533161A5 (cg-RX-API-DMAC7.html)
JP2023504016A5 (cg-RX-API-DMAC7.html)
JP2023507729A5 (cg-RX-API-DMAC7.html)
JP2021508469A5 (cg-RX-API-DMAC7.html)
JP2017504577A5 (cg-RX-API-DMAC7.html)
JP2020114210A5 (cg-RX-API-DMAC7.html)
JP2013527761A5 (cg-RX-API-DMAC7.html)
JP2017504578A5 (cg-RX-API-DMAC7.html)
JP2020510422A5 (cg-RX-API-DMAC7.html)
RU2013142600A (ru) Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы
JP2014518615A5 (cg-RX-API-DMAC7.html)
JP2021511811A5 (cg-RX-API-DMAC7.html)
JP2018523493A5 (cg-RX-API-DMAC7.html)
JP2020522474A5 (cg-RX-API-DMAC7.html)
JP2020510659A5 (cg-RX-API-DMAC7.html)